Previous studies in this laboratory have quantified the fibrinolytic activity of herpesvirus-transformed cell lines and implicated the proteolytic capacity of cloned cell lines in the formation of primary and metastatic tumours. Because of the involvement of proteases in tumourigenesis in this system, we examined the effect of various protease inhibitors (a-1-antitrypsin, leupeptin and a-2-macroglobulin), as well as hamster serum containing acute phase proteins generated in response to physiological trauma, on the fibrinolytic capacity of a herpes simplex virus type 2-transformed hamster cell line. The effects of the various inhibitors on cell growth, fibrinolysis in vitro and tumourigenesis were examined. Leupeptin, ~-1-antitrypsin, a-2-macroglobulin and hamster serum containing acute phase proteins were capable of inhibiting fibrinolysis in vitro, were not toxic to the cells and their action was reversible, while injection of a mixture of protease inhibitor and transformed cells resulted in delayed tumour development.
INTRODUCTION
The role of proteases in tumourigenicity has been the target of many investigations. Cells transformed by viruses or chemicals, cells derived from tumour biopsies and certain types of normal cells that exhibit transient invasiveness produce elevated levels of proteases. The invasiveness of such cells may be a direct result of their ability to disrupt surrounding tissue (Ossowski et al., 1975) . (For thorough reviews, see Reich et al., 1975; Striiuli et al., 1980; Kline & Reddy, 1980.) It has been demonstrated that cells transformed in vitro by herpes simplex virus (HSV) or human cytomegalovirus (Howett et al., 1978; Yamanishi & Rapp, 1979) have increased protease activity compared with normal control cells. This activity is plasminogen-dependent and, therefore, represents increased levels of the serine protease plasminogen activator (PA). Quantification of the end-product of PA activity, i.e. plasmin, is possible by measuring fibrinolysis of radioiodinated fibrin (Unkeless et al., 1973) . Fibrinolysis by HSV-transformed hamster cell lines has been quantified in our laboratory and we have also demonstrated that increased PA activity is induced in cells early after infection with a transforming dose of partially inactivated HSV type 2 (HSV-2; Adelman et al., 1980) . Subpopulations of the HSV-2-transformed hamster cell line 333-8-9 were selected in vitro for increased fibrinolytic activity, and increased PA activity was correlated with early tumour formation in vivo (Adelman et al., 1981) . Because the protease activity of these transformed cells appears to play a role in their tumourigenicity, we studied the effect of protease inhibitors on cell growth and fibrinolysis in vitro and on the development of tumours in vivo. We tested three well-characterized protease inhibitors, ct-l-antitrypsin (alA), ct-2-macroglobulin (a2M) and leupeptin, as well as acute phase serum proteins for anti-fibrinolysis. 
METHODS
Cell culture. Virus-transformed cells were derived from the established hamster cell line 333-8-9, originally transformed in vitro with HSV-2 strain 333 partially inactivated by u.v. light (Duff & Rapp, 1971) . Cell lines 333-8-9 (282), 333-8-9 (C6) and 333-8-9 (B 6) were derived by single-cell subcloning of the parental (333-8-9) cell line, and were selected for increased fibrinolytic activity, as compared to the parental cell line (Adelman et al., 1981) . The parental line and all subclones were routinely maintained in medium 199 containing 10% foetal calf or donor calf serum, 10% tryptose-phosphate broth, 0.225% bicarbonate and either 50 gg/ml chlortetracycline or 5 gg/ml gentamicin. Cells to be assayed for fibrinolytic activity were fed the same medium supplemented with acid-treated serum rather than regular serum. Acid treatment is reported (Ossowski et al., 1975) to destroy protease inhibitors in serum and is routinely used when assaying for PA because this allows precise addition of protease inhibitors. Acid-treated serum was prepared as described previously (Ossowski et al. 1975) . Cell counts were routinely made by the trypan blue exclusion method.
~25I-labelledfibrin lysis assay. Assay of fibrinolysis was performed as described previously (Unkeless et al., 1973; Adelman et al., 1980) . Briefly, ~25I-labelled fibrinogen (105 ct/min/plate) was diluted with cold fibrinogen, pipetted into plastic dishes and spread evenly over the surface to dry. The dried fibrinogen was exposed to u.v. light for 30 min to prevent bacterial growth. Either purified bovine thrombin (5 U/ml) or cell culture maintenance medium containing foetal or donor calf serum as a source of thrombin was added to the plates to convert the fibrinogen to fibrin. The plates were then washed to remove any free ~25I-labelled fibrinogen. Medium containing plasminogen from the test cell lines was placed on 125I-labelled fibrin-containing plates and incubated to allow plasmin in the test cell medium to release monomeric 125I-labelled fibrin into the fluid. The monomers were then quantified in a gamma counter. The amount of 125I-labelled fibrin monomers is proportional to the amount of plasmin generated in the test medium by the action of PA. The detection of PA activity from HSV-transformed cells has been described in detail previously (Adelman et al., 1980 (Adelman et al., , 1981 .
Protease inhibitors, atA (human) and leupeptin were purchased from Sigma and o,2M (human) from Calbiochem. a~A was diluted in physiological tris-buffered saline and stored at -20 °C. Both leupeptin and a2M were stored at 4 °C and were freshly prepared before dilution in cell culture medium. Acute phase serum proteins were induced in hamsters by subcutaneous injection of 0-5 ml turpentine. The animals were exsanguinated 48 h after injection.
Animals. Newborn LAK/LSH inbred hamsters were used in all animal experiments described. For tumour studies, animals were injected subcutaneously on the back (2 litters/group) within 24 h of birth with cells suspended in 0.05 ml of transformed-cell maintenance medium, plus or minus the chosen inhibitor. Animals were palpated weekly for tumour development.
RESULTS

Effect of protease inhibitors on cell growth
Four cell lines were tested for cell growth in the presence of (; , 333-8-9 (B6) and 333-8-9 (C6)] were selected from the parental cell line (333-8-9) because of enhanced fibrinolytic activity. All cell lines were exposed to culture medium containing 10% acid-treated serum during the test conditions.
After seeding, cells were fed medium containing acid-treated serum plus 50/tg/ml alA, or medium without inhibitor. On days 1, 2, 4 and 7 after selected medium was added, medium was removed from appropriate plates and saved for fibrinolysis assay. The cells were trypsinized and counted by the trypan blue exclusion method. Each of the four cell lines exposed to the alA grew at approximately the same rate as those not exposed to inhibitor (Fig. 1) . Because the concentration of %A used in this experiment (50/~g/ml) was in 100-fold excess of the concentration needed to suppress the fibrinolytic activity of the cells, we concluded that UlA was not toxic to cell growth. Studies similar to those described above were carried out with %M and leupeptin. Growth of 333-8-9 cells exposed to medium containing 100/~g/ml %M or 10 ~g/ml leupeptin did not differ from that of cells exposed to medium without inhibitor (data not shown). We therefore concluded that neither a2M nor leupeptin was toxic to the cells.
Effect of protease inhibitors on fibrinolytic activity in vitro
The effect of %A on the ability of known PA producers to generate plasmin in vitro was assessed in the 333-8-9 and 333-8-9 (282) cell lines. Cells were seeded, fed normal maintenance medium for 4 days and then washed and refed medium containing 10% acid-treated serum. This medium, after 24 h of additional incubation, was utilized in a standard fibrinolysis assay to measure the effect of ctlA (0, 0.5, 5 or 50/~g/ml) on fibrinolysis. At the time medium was removed from the wells for PA testing, the cells were counted. The results of this experiment (Table 1) show that (i) medium incubated for 24 h with 0.5, 5 or 50 Bg/ml alA suppressed the fibrinolytic activity of the cell culture medium from either the 333-8-9 or the 333-8-9 (282) cell lines, and (ii) the concentration of aIA used to test its cell toxicity (see Fig. 1 ) was 100-fold higher than the concentration sufficient to suppress fibrinolytic activity. In conjunction with this experiment, duplicate wells to those described above had their medium removed, the cells were washed twice to remove inhibitor, and the S. F. ADELMAN, M. K. HOWETT AND F. RAPP 1.31 49.50 * Cells were seeded into 16-mm plates, allowed to grow for 4 days, washed and then exposed to fresh medium containing acid-treated foetal calf serum plus or minus inhibitor.
t After incubation described in (*), medium was removed from two plates of each inhibitor concentration and the medium was tested in duplicate for ability to release 125I-labelled fibrin monomers; the cells from each plate were counted. ~: After incubation for 24 h with cqA, medium was also removed from an additional two plates of each inhibitor concentration, the plates were washed and fresh medium containing acid-treated serum was replenished for an additional 24 h. After this incubation this medium was removed, assayed for fibrinolysis and the cells were counted. cells were refed medium containing acid-treated serum for an additional 24 h. Twenty-four h after inhibitor reversal, the medium was removed for 125I-Iabelled fibrin lysis assay, and the cells were also counted. The data (Table 1) indicate that suppression of fibrinolysis was rapidly reversible. By 24 h after removal of exogenous inhibitor, the fibrinolytic activity of the new medium was similar to that of medium taken from cells never exposed to inhibitor.
We also measured the fibrinolytic capacity of medium alone and medium containing alA after continuous exposure to cells for 1, 2, 4 or 7 days. The medium used was taken from cells used in the alA toxicity experiment (described in Fig. 1 ). Plates containing 333-8-9, 333-8-9 (282), 333-8-9 (Bd) or 333-8-9 (C6) cells were exposed to medium containing acid-treated serum and 0 or 50/~g/ml uzA for 1, 2, 4 or 7 days. On each day, medium was removed from duplicate plates and tested for fibrinolytic activity. The cells were then counted as described earlier. The results of this study are shown in Fig. 2 . The presence of the inhibitor suppressed the fibrinolytic capacity of the medium samples for a period of at least 4 days. By day 7, protease activity was still significantly suppressed although not as extensively as during the initial 4-day incubation period.
In addition to suppression of fibrinolytic activity with alA, the effect of a2M and leupeptin was examined. Experiments attempting to demonstrate in vitro suppression of fibrinolytic activity by a2 M and leupeptin were set up simultaneously with the cell growth experiments. On days 1, 2, 3 or 4 after exposure of 333-8-9 cells to the inhibitor, medium samples were removed from the cells before cell counting. These medium samples were subsequently tested for ability to release ~25I-labelled fibrin monomers by the standard assay (Table 2) . Cells not exposed to exogenous protease inhibitors showed increased fibrinolytic activities compared with cells exposed to either a2 M or leupeptin. Throughout the 4-day exposure to either inhibitor, fibrinolytic activity was significantly suppressed.
In vitro inhibition of fibrinolytic activity produced by HS V-2-transformed cells by hamster serum containing acute phase reactants (APR )
During the acute phase, a fivefold increase in protease inhibitor levels in serum is seen 48 h after trauma (Jordan, 1976) . Therefore, it was of interest to determine whether serum containing APR could suppress the fibrinolytic activity of our cell system. The effects of hamster serum containing APR on the fibrinolytic activity produced by virus-transformed Medium with or without cqA was added to a series of plates at time zero. On days 1, 2, 4 and 7 after addition, medium was removed from two plates of each cell line and assayed for fibrinolysis. Two determinations per plate were carried out; therefore, each point represents an average of four determinations. (c) and (d) show samples capable of greater than 100% fibrinolysis because diluted medium samples (1:2) were used in the fibrin lysis assay and the resulting data were normalized by multiplication by 2. 
333-8-9 (282)
Hamster serum + plasminogen 76-7 _+ 0-33 Acute phase hamster serum + plasminogent 16.1 + 0.46 * All medium control samples were exposed only to the t:SI-labelled fibrin-coated plates and not to cells. t Purified bovine plasminogen was used here at a concentration of 100/~g/ml.
hamster cells were examined. Of 10 inbred hamsters (weight 100 to 120 g, approx. 6 months old) 5 were injected subcutaneously with 0.5 ml turpentine. Forty-eight h after injection, the 10 hamsters were sacrificed by cardiac puncture, and normal and acute phase sera were made from the hamster blood. We first examined inhibition of cell-associated fibrinolytic activity produced by transformed cells. Cell culture medium was prepared by substituting the 10% acid-treated serum routinely used in the fibrinolysis assay with either 10% normal hamster serum or 10% acute phase hamster serum. The medium was incubated with the transformed cells for 24 h, and then removed and tested by lzSI-labelled fibrin lysis assay. The cells were subsequently counted by trypan blue exclusion (Table 3 ). The fibrinolytic activity of the transformed cells (333-8-9) or the high PA-producer cells [333-8-9 (282) ] was significantly depressed in the presence of hamster serum containing APR, whereas cells exposed to normal hamster serum showed levels of fibrinolytic activity similar to those exposed to cell culture medium containing acid-treated serum (see Table 1 ). Treatment for 24 h with cell culture medium containing 10% acute phase hamster serum was not toxic to the cells (data not shown).
The experiment described above measured cell-associated PA since plasminogen was present in the medium during the 24 h of exposure to ceils. It is possible to measure extracellular PA by incubating cells in medium that lacks a plasminogen source and adding plasminogen to the medium samples after removal from the cells. Extracellular PA can then cleave plasminogen to plasmin. Herpesvirus-transformed cells can produce extracellular PA (Adelman et al., 1980) . Serum-free and therefore plasminogen-free medium was incubated with 333-8-9 and 333-8-9 (282) cells for 24 h after removal of medium. Normal hamster ~" Numbers indicate weeks after injection.
serum or acute phase hamster serum was added to the medium samples to a final concentration of 10 %. To ensure that the plasminogen source for PA was adequate, bovine plasminogen was also added (100 #g/ml). This mixture was incubated at 37 °C for 30 min to allow possible generation of plasmin. The medium samples were then tested for fibrinolysis. Table 4 demonstrates that fibrinolysis by serum-free medium samples exposed to cells and then incubated with acute phase hamster serum plus plasminogen was low compared with fibrinolysis by similar medium samples containing normal hamster serum. Thus, the data in Tables 3 and 4 show that induction of acute phase proteins in the serum of normal hamsters can inhibit the fibrinolytic activity produced by syngeneic cells. It is unknown whether this inhibition is due to blockage of plasminogen conversion to plasmin or to inhibition of plasmin-mediated fibrinolysis.
Decreased tumourigenic potential resulting from protease inhibition with protease inhibitors in vivo
Because we had previously shown that PA levels in HSV-2-transformed cells correlated well with cellular tumourigenicity, we felt that inhibition of protease function might favourably alter the outcome of tumour development in syngeneic hamsters injected with the cells as newborns. The animals in this study were injected with 0.05 ml of cell culture medium containing 2 × 10 v transformed cells [333-8-9 or 333-8-9 (B6)] mixed with aIA to a final concentration of 50 #g/ml per newborn hamster. Experimental and control groups, each composed of two litters of animals, were observed and palpated weekly for the appearance of primary subcutaneous tumours (Fig. 3) . Fig. 3 (a) shows tumour development in animals inoculated with parental cell line 333-8-9. Animals injected with cells exposed to protease inhibitor showed delayed tumour development compared with hamsters receiving only transformed cells. Fig. 3 (b) shows tumour development in animals inoculated with the very high PA-producer cell line 333-8-9 (B6). Again, animals exposed to the protease inhibitor showed a decreased rate of tumour appearance. By week 12 all animals in all test groups had developed primary subcutaneous tumours (data not shown).
We also examined suppression of tumour development by admixing ~2 M or leupeptin with tumour cells before injection. The protocol followed in this study was similar to that described above for a~A. Only the parental cell line was used. Each animal received 0.05 ml of cell culture medium containing 2 x 107 cells with or without a2 M (100 #g/ml) or leupeptin (10 #g/ml). Each combination was injected into two litters of newborn hamsters. These animals were also observed and palpated weekly for the appearance of primary subcutaneous tumours ( Table 5 ). Animals that received only transformed cells developed palpable tumours 6 weeks after inoculation, whereas animals inoculated with a mixture of cells and inhibitor (either a2 M or leupeptin) did not develop tumours until 9 weeks after injection. In addition, the control group developed a 100% tumour incidence more rapidly than either the ~2 M or leupeptin experimental groups. s.F. ADELMAN, M. K. HOWETT AND F. RAPP DISCUSSION A wide spectrum of animal, microbial and synthetic protease inhibitors have been described (for reviews, see Baugh & Schnebli, 1980; Collen, 1980) . For example, protease inhibitors comprise 10% of the proteins of normal human serum, and regulate normal protease functions (Heimburger, 1975) . Altered plasma levels of inhibitors are associated with various diseases or with a non-specific defence mechanism, the 'acute phase,' during which several protease inhibitors increase in serum concentration as an anti-inflammatory response. Enumeration of protease inhibitors and elucidation of their specific mechanism of action are far from complete (Baugh & Schnebli, 1980) . ~IA, the most abundant human plasma protease inhibitor, is a single polypeptide chain with a mol. wt. of approx. 54000 to 55 000. Also referred to as cx~-proteinase inhibitor, txtA is an APR (Travis et al., 1974; Heimburger, 1975; Jeppsson & Lanrell, 1975; Str~iuli et al., 1980) and inhibits a broad spectrum of serine proteases (Baugh & Schnebli, 1980) . Although its exact role is not completely understood, alA appears to complex with proteases in the extracellular space and re-enter the plasma where interaction with 0L2M may occur. Complexes of alA and proteases may be metabolized directly by the liver (Kress & Laskowski, 1974). cI2M is also a plasma protease inhibitor and has a mol. wt. of 725 000. It is roughly 15 times less abundant than tXlA (3.5 M in human plasma) but has the broadest spectrum of inhibition (Barrett & Starkey, 1974; Harpel, 1976; Starkey & Barrett, 1977) . cx2M is considered one of the main defensive proteins in human plasma (Heimburger, 1975; Bangh & Schnebli, 1980) and an APR that neutralizes excess plasmin (Heimburger, 1975; Collen, 1980) . It has been suggested that enzymes such as trypsin may be bound initially by ¢qA, transferred to ct2M, and then cleared from the blood with a half-life of about 8 min (Collen, 1980) . Due to its high tool. wt., ~2 M diffuses poorly into tissues and is thought to function primarily in the vascular space (Harpel et al., 1975) . ~2 M is believed to combine with proteases irreversibly and on a one-to-one molar basis; however, the mechanism of action is unclear since the inhibitor is not consumed during degradation of the inactivated protease (Heimburger, 1975) .
Leupeptin is a low mol. wt. protease inhibitor produced by Actinomycetes (Wingender, 1974; Aoyagi & Umezawa, 1975; Umezawa, 1977; Umezawa & Aoyagi, 1977; Frommer et al., 1979) and contains an aldehyde group that reacts with the hydroxyl group of the active-site serine in serine proteases to form stable intermediates (Baugh & Schnebli, 1980) . Studies conducted with leupeptin have been reviewed by Aoyagi & Umezawa (1975) . After administration to animals, leupeptin is excreted in urine without hydrolysis, can suppress pain and blister formation following burns, and shows anti-inflammatory effects. In addition, leupeptin inhibits phytohaemagglutinin-stimulated DNA synthesis in lymphocytes (Saito et aL, 1972 (Saito et aL, , 1973 . This compound has also been reported to inhibit promotion by croton oil or phorbol ester of tumourigenesis in mouse skin initiated by dimethylbenzanthracene (DMBA; Troll et al., 1970; Hozumi et al., 1972) . Additional protease inhibitors have also been tested for their effects on cells transformed by DMBA in vitro. It was found that growth and morphology of tumour cells could be modified by exposure to inhibitors (Goetz et al., 1972) .
The results of our in vitro studies clearly indicate that the addition of protease inhibitors to cultures of established cell lines transformed by HSV-2 can suppress the fibrinolytic activity of the cells, a~A, a2M or leupeptin were all effective and did not affect cell growth. It is not known at this time whether these inhibitors block plasminogen activation directly or interfere with the end-product of activation, plasmin.
The possible effect of protease inhibitors on tumours and tumourigenesis has been previously addressed. his co-workers (1970, 1978) have inhibited tumour promotion but not tumour initiation with several synthetic inhibitors, whereas Umezawa (1976 Umezawa ( , 1978 has inhibited growth and metastasis of several types of experimental tumours using the microbial proteinase inhibitors leupeptin and bestatin. Collen et al. (1977) have shown that anti-plasmin can inhibit the fibrinolytic activity and tumourigenesis of mouse fibroblasts transformed by Kirsten murine sarcoma virus. Lage et al. (1978) have also shown moderate inhibition of experimental tumours using aprotinin. However, chemical carcinogenesis in rat bladders may be promoted by leupeptin (Kakizoe et al., 1977) and initial attempts to suppress metastatic tumour growth in an experimental herpesvirus tumour system were unsuccessful (Harvey et al., 1977) . In an attempt to accomplish this last goal, we utilized inhibitors from a variety of sources that share the ability to suppress the broad-spectrum protease plasmin.
In summary, a variety of exogenous protease inhibitors can affect the fibrinolytic capacity of HSV-2-transformed hamster cells as detected in vitro by 125I-labeUed fibrin lysis assay. These inhibitors also appear to have an effect on tumourigenesis. The enzyme PA and its end-product plasmin obviously play an important biological role in tumour development in this system. Experiments are in progress to determine the molecular level at which the inhibition occurs and whether multiple administrations of protease inhibitors will enhance the effects already seen.
